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SHORT SUMMARY  
In people living with HIV who participate in the Swiss HIV Cohort Study, we observed state-
of-the-art performances in forecasting individual onsets of chronic kidney disease with 
different machine learning algorithms.   
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ABSTRACT  
Background: It is unclear whether data-driven machine learning models, which are trained 
on large epidemiological cohorts, may improve prediction of co-morbidities in people living 
with HIV. 
Methods: In this proof-of-concept study, we included people living with HIV of the 
prospective Swiss HIV Cohort Study with a first estimated glomerular filtration rate (eGFR) 
>60 ml/min/1.73 m2 after January 1, 2002. Our primary outcome was chronic k dney disease 
(CKD) ─ defined as confirmed decrease in eGFR ≤60 ml/min/1.73 m2 over three months 
apart. We split the cohort data into a training set (80%), validation et (10%), and test set 
(10%) ─ stratified for CKD status and follow-up length.  
Results: Of 12,761 eligible individuals (median baseline eGFR, 103 ml/min/1.73 m2), 1,192 
(9%) developed a CKD after a median of eight years. We used 64 static and 502 time-
changing variables: Across prediction horizons and algorithms and in contrast to expert-based 
standard models, most machine learning models achieved state-of-the-art predictive 
performances with areas under the receiver operating characteristic curve and precision recall 
curve ranging from 0.926 to 0.996 and from 0.631 to 0.956, respectively.  
Conclusions: In people living with HIV, we observed state-of-the-art performances in 
forecasting individual CKD onsets with different machine learning algorithms.  
 
Keywords: chronic kidney disease; digital epidemiology; HIV; machine learning; prediction.   
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INTRODUCTION  
With the advent of combined antiretroviral therapy, HIV-related morbidity and mortality 
have continuously decreased ─ with people living with HIV having nowadays, under optimal 
conditions, an almost identical life expectancy to the general population [1-4]. As HIV 
infection has become a chronic condition, accurate prediction of primarily non-HIV-related 
co-morbidities such as chronic kidney disease (CKD) have gained importance in the 
individualised care of people living with HIV [5].  
 
As the occurrence of CKD and of other non-HIV-related chronic conditions may be 
influenced by hundreds of potentially interacting, static and time-changing factors across the 
healthcare continuum, data-rich and well-curated HIV cohorts may offer ideal conditions to 
develop machine learning models and to validate their usefulness to optimise personalised 
prevention and treatment strategies in people living with HIV. Cohort-based machine 
learning is an evolving field in digital epidemiology, which has the potential to improve 
decision support and underlying prediction models [6, 7]. Previous prediction models of CKD 
and of other multifactorial conditions may be limited, as it is challenging to account for 
complex interactions and to analyse high-dimensional datasets (i.e. data collections with a 
multitude of variables) with standard regression models. Conversely, some machine learning 
prediction models have limited generalisability to other settings with intransparent 
predictions for single individuals [8].  
 
In the present proof-of-concept study conducted in people living with HIV, we aimed to 
evaluate different machine learning algorithms and modeling strategies for individual CKD 
prediction in order to exemplify whether machine learning models can be readily trained in a 
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7 
high-dimensional cohort setting. The resulting machine learning prediction models of CKD 
onsets may become part of an integrated decision support tool for shared decision-making 
and personalisation of prevention and treatment strategies in people living with HIV. In a 
wider context, our investigation may be helpful for current large-scale cohorts to assess the 
feasability and challenges with cohort-based machine learning prediction. 
 
METHODS  
Swiss HIV Cohort Study 
The Swiss HIV Cohort Study (SHCS; www.shcs.ch) is a nationwide, prospective multicentre 
cohort study with semi-annual visits and blood collections ─ having enrolled >20,000 HIV-
infected adults who live in Switzerland [9]. The SHCS is representative of the HIV epidemic 
in Switzerland [9]. A standardised protocol is used in the SHCS for data collection: Socio-
demographic and clinical data are recorded at study entry and various laboratory tests are 
routinely performed at registration. At each follow-up visit, extensive laboratory, clinical and 
treatment information is recorded. Additional interim laboratory and clinical evaluations are 
recorded, if available. The SHCS is registered on the longitudinal study platform of the Swiss 
National Science Foundation (www.snf.ch/en/funding/programmes/longitudinal-studies).  
 
For the training of pragmatic and individualised machine learning models, most SHCS 
variables have been used, but potentially identifying variables (including living/working 
situations), information on sexual behaviour, variables recorded only within a short period, 
genetic/-omics data, and some metadata (e.g. name of study nurse) were omitted as defined a 
priori in the study group and as discussed with a national representative of people living with 
HIV. Where applicable, we followed ‘The Strengthening the Reporting of Observational 
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8 
Studies in Epidemiology’ and the ‘Transparent Reporting of a Multivariable Prediction 
Model for Individual Prognosis Or Diagnosis’ statement when reporting our study results [10, 
11]; furthermore, we used the reporting criteria developed by Luo et al. (2016) [12].  
 
Study population and definitions 
After January 1, 2002, when calibrated creatinine measurements were incorporated in the 
SHCS, we included HIV-infected individuals aged ≥18 years with a baseline estimated 
glomerular filtration rate (eGFR) >60 ml/min/1.73 m2 ─ independent of antiretroviral 
treatment regimens/status ─ and at least three calibrated serum creatinine measurements 
before October 10, 2018. Individuals with a baseline eGFR ≤60 ml/min/1.73 m2, less than 
three creatinine measurements, and/or less than three months of follow-up were excluded.  
 
We defined the baseline as the first creatinine measurement after January 1, 2002. We 
followed individuals from baseline until occurrence of CKD or the last recorded creatinine 
measurement, whichever came first. However, we used horizons of three to twelve months 
for machine learning prediction of CKD onset. 
 
We defined CKD, our a priori primary outcome, as a confirmed (over three months apart) 
decrease in eGFR ≤60 ml/min/1.73 m2, in line with the ‘Kidney Diseases ─ Improving 
Global Outcomes’ algorithm and previous large-scale investigations on CKD in people living 
with HIV [5, 13]. As a measure of kidney function, we calculated the eGFR using the well-
established ‘Chronic Kidney Disease Epidemiology Collaboration’ equation, which had been 
validated extensively in people living with HIV [14-17].  
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9 
All participants in the SHCS provided informed consent and the study was approved by the 
ethical committees of the respective participating centers (EKNZ project No. 2017─02252). 
We report deviations from the study protocol in the appendix (page 3).  
 
Predictive modeling  
We trained a set of data-driven machine learning models (full models) to predict CKD events 
within prespecified prediction horizons ─ representing a classification problem, which relied 
on both static and irregularly sampled time and event series data. We applied the following 
five machine learning algorithms for CKD prediction with single patient visits as unit of 
observation and parameter tuning (selection) on the validation set:  
 
(i) Elastic net is a regularised, linear logistic regression method that includes both the lasso 
(L1) and the ridge (L2) penalty via a linear combination [18]. It optimises the following 
objective: 
max
𝛽,𝜆,𝜈
log∑ log𝑝(𝑦𝑖|𝑥𝑖, β𝑖)
𝑁
𝑖=1
+ λ||𝛃||
2
+ ν||𝜷||
1
 
where {(𝑥1, 𝑦1), (𝑥3, 𝑦2), … , (𝑥𝑁, 𝑦𝑁)} is the training dataset, and ,  and  are the model 
parameters. 
 
(ii) Random forest models [19] average a collection of decorrelated classification or 
regression trees, in which a prespecified number of trees are fitted ─ each on a separate 
bootstrap sample drawn with replacement from the training data. We describe the details of 
the algorithm in appendix table 1. 
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(iii) Gradient boosting machine [20] is an ensemble approach that iteratively adds simple 
models to the ensemble such that in each iteration a new model is trained with respect to the 
updated error of the ensemble learned in the previous iteration. We describe the details of the 
respective training algorithm in appendix table 2. 
 
(iv) Multilayer perceptron [21] is a non-linear machine learning approach ─ representing a 
feedforward neural network with at least three fully connected layers. We used the rectified 
linear unit: 
𝑓(𝑥) = max(0, 𝑥) as activation function.  
 
(v) Recurrent neural networks (RNNs) are artificial neural networks that use a directed graph 
to model the connections between the nodes and are thus directly applicable to temporal 
sequence data. We used the ‘Long Short Term Memory’ (LSTM) architecture [22]. We 
describe the details of the respective training algorithm in appendix table 3.  
 
For comparison with data-driven machine learning models, we have manually built logistic 
regression models (short models) for the different prediction horizons – in analogy to the 
well-established full risk score model by Mocroft et al. for prediction of CKD in people 
living with HIV.13 We used the following predictors: HIV exposure through intravenous drug 
use (yes, no, or unknown), hepatitis C coinfection (yes or no), birth year, estimated 
glomerular filtration rate until day of prediction (normalized scale; modelled as described for 
the data-driven machine learning models), sex (male or female), CD4 count until day of 
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11 
prediction (normalized scale; modelled as described for the data-driven machine learning 
models), hypertension (yes, no, or unknown), prior cardiovascular diseases (yes or no), and 
diabetes mellitus (yes or no). Our manually built logistic regression models use the last two 
most recent measurements of the considered variables along with the summary statistics of all 
their previous measurements. 
 
Dataset representation 
To train our machine learning models, we extracted the anonymised study data from the 
SHCS main database ─ comprising a vast collection of static and time-changing (dynamic) 
variables, which were often irregularly measured as part of the clinical routine. The RNN-
based methods process sequences of inputs and can thus use the visit sequence directly. For 
the remaining machine learning methods, the input information for each individual is a 
concatenation of the information from the two last (most recent) hospital visits and the 
corresponding summary statistics (mean, median, max, standard deviation) from all previous 
visits. Note that the visit sequence for each patient is derived from the considered observation 
period determined by the target prediction horizon and the last (most recent) visits refer to 
these derived sequences. We describe the detailed data representation and missing value 
imputation strategy in the appendix (page 4).  
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Model evaluation  
To evaluate the performance of the different machine learning approaches and models, we 
split all study data into three subsets, namely a training set, a validation set and a test set. We 
created the validation and test sets by randomly sampling (without replacement) 10% of the 
study population. The sampling was stratified with respect to the follow-up length and CKD 
status, i.e. 10% of individuals were at first randomly sampled from the group of individuals 
that have developed CKD and then 10% were randomly sampled from the group of the 
individuals that did not develop CKD. The remaining 80% of the individuals comprised the 
training set.  
 
We applied each of the described machine learning methods to predict CKD events as a set of 
adjusted hyperparameters to deliver accurate predictions on unseen data. We performed the 
model selection/hyperparameter tuning process on the validation set. Finally, we evaluated 
the predictive performance of the best-performing model for each considered approach on the 
test set (reported in the results section). We considered four different evaluation scenarios, 
each with a different prediction horizon, namely 90, 180, 270, and 365 days. The prediction 
horizon specifies how many days in advance we aimed to predict the occurrence of CKD 
where the time of diagnosis is determined by the second eGFR measurement of the CKD 
definition used. 
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13 
Performance measures 
Due to the large CKD imbalance in our dataset (i.e. most individuals did not develop CKD), 
the classification accuracy was not suitable to measure the models’ performance. Therefore, 
we calculated five well-established measures for the class imbalance scenario; namely, the F-
score, precision (i.e. positive predictive value), recall (i.e. sensitivity), area under the receiver 
operating characteristic curve (ROC-AUC), and area under the precision recall curve (PR-
AUC). The precision, recall and F-score are defined as follows: 
 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =
TP
TP + FP
 
𝑅𝑒𝑐𝑎𝑙𝑙 =
𝑇𝑃
𝑇𝑃 + 𝐹𝑁
 
𝐹 − 𝑠𝑐𝑜𝑟𝑒 =
2 ∙ 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 ∙ 𝑅𝑒𝑐𝑎𝑙𝑙
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑅𝑒𝑐𝑎𝑙𝑙
 
 
where TP denotes the true positives, FP denotes the false positives, FN denotes the false 
negatives and positives refer to the minority class (in our case individuals with CKD onset).  
 
The precision recall curve is a plot of the recall versus the precision for all possible decision 
thresholds. As the precision and recall focus only on the correct prediction of the minority 
class (i.e. CKD), the F-Score and the PR-AUC reflect the model’s prediction quality for CKD 
events. The receiver operating characteristic curve is a widely used plot of the false positive 
rate (the proportion of false positives out of all negatives) versus the true positive rate (the 
proportion of true positives out of all positives) for all possible decision thresholds. The 
ROC-AUC thus illustrates the ranking ability in binary classification: A ROC-AUC of, for 
instance, 0.80 indicates that 80% of the predictions are correctly classified (for pairs of 
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14 
individuals with and without the endpoint). For model selection, we used the F-score for the 
RNN-based approaches and the log loss for the remaining approaches.  
 
Due to the time-consuming model selection process, we performed all experiments and 
computed all relevant evaluation metrics for one training, validation and test split. We believe 
that our results reflect the predictive quality of the considered machine learning models, as 
our test set was fairly large.    
 
RESULTS 
Within the study period, 12,761 individuals were included in the final analysis ─ with 10,209 
(80%), 1,276 (10%), and 1,276 (10%) of participants’ prospectively collected cohort records 
contributing to the machine learning model training, validation, and test sets, respectively 
(figure 1). We describe the main characteristics of the study population in table 1: Overall, 
1,192 of 12,761 (9%) individuals developed a CKD within the study period; the median 
follow-up in individuals with and without CKD was 8 years (interquartile range [IQR], 4 to 
12 years) and 9 years (IQR, 4 to 15 years), respectively.  
 
We describe the eGFR distribution of individuals with and without CKD in figure 2: At 
baseline, eGFR distributions were partly overlapping between individuals with and without a 
subsequent CKD ─ with increased eGFRs of individuals without subsequent CKD onset 
across prediction horizons. For individuals with and without subsequent CKD, the overlap in 
eGFR distributions increased over longer prediction horizons. Overall, at day of prediction, 
the frequency of subsequent eGFR measurements within 365 days was slightly increased for 
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15 
individuals with a decreased eGFR of ≤60 ml/min/1.73 m2 compared to individuals with 
eGFRs >60 ml/min/1.73 m2 (median, 1.8 measurements per month; IQR, 1.0 to 2.5; versus; 
median, 1.5 measurements per month; IQR, 0.7 to 2.3).  
 
We used 64 static and 502 dynamic variables for machine learning model development (full 
models) ─ including 28 demographic variables, 159 variables pertaining to treatment 
information, 93 laboratory variables, and 286 clinical variables: Across prediction horizons 
and machine learning algorithms, most models achieved similar predictive performances with 
ROC-AUCs and PR-AUCs ranging from 0.926 to 0.996 (i.e. 92.6% to 99.6% of predictions 
are correctly classified for pairs with and without CKD) and from 0.631 to 0.956, 
respectively (table 2). In regard to ROC-AUCs and PR-AUCs, the machine learning models’ 
classification performance can be considered as excellent and moderate to excellent, 
respectively: The PR-AUCs were lower than the corresponding ROC-AUCs, as CKD events 
were relatively rare. For comparison with the full machine learning models, we have 
manually built logistic regression models (short models) based on well-established predictors 
(table 2): In most cases, these short models had a worse predictive performance than the full 
machine learning models for CKD prediction.  
 
For illustration purposes, we describe in figure 3 the variable importance of the highest 
scoring predictors for the gradient boosting model (prediction horizon, 180 days): Overall, 
the eGFR information was the most important marker for CKD prediction within 180 days. 
Across prediction horizons, we describe the gradient boosting models’ output and individual 
key predictors for three complex cases (table 3): Information on predicted outcome 
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16 
probabilities and the individual variable importance can be obtained for all applied machine 
learning algorithms to increase the interpretability/transparency of machine learning models 
and to potentially personalise prevention and treatment decisions.    
 
The preparation and structuring of our datasets for machine learning training required one-
month full-time work. The RNN-based model selection procedure was computing-intensive 
and required 20 to 30 hours on a high-performance computing cluster. The corresponding 
computing time for model selection among the remaining non-linear approaches was in the 
order of one to two hours each. The final model training was fast for all machine learning 
methods except for the RNN-based methods, which required approximately 30 minutes. 
Obtaining individual predictions with a trained model was fast (couple of minutes at most) 
for all machine learning methods.  
 
 
DISCUSSION  
In this large cohort study, we have developed pragmatic machine learning models to predict 
CKD onset and derive CKD development probabilities at the point of care in single 
individuals living with HIV. The respective machine learning models had a rather high 
predictive performance despite using prediction horizons of three to twelve months, which 
may decrease the precision (i.e. positive predictive value) for CKD predictions. We measured 
our machine learning models’ predictive power by a set of well-established metrics to 
improve the comparability across models and studies. In contrast to previous studies, we have 
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17 
included a multitude of static and dynamic factors in our prediction models (data-driven 
machine learning modeling), which resulted mostly in improved performances for CKD 
prediction compared to manually built regression models based on a few predictor variables 
(table 2) [13, 23]. Our proof-of-concept study provides a “reality-check” of the feasability of 
machine learning prediction studies nested within large epidemiological cohorts.   
 
To the best of our knowledge, this is the first study, in which different machine learning 
models have been developed and internally validated in people living with HIV for 
individualised CKD prediction. Previous studies have developed standard regression-based 
models and scores (e.g. by use of Poisson regression) for long-term CKD prediction, which 
had a good discrimination in external validation [5, 13, 23, 24]. For instance, as part of the 
‘Data Collection on Adverse Events of Anti-HIV Drugs’ study, a full and short risk score 
were developed to predict CKD over 5 years (but not for shorter prediction horizons) ─ with 
the short risk score demonstrating a relatively good predictive performance in external 
validation (ROC-AUC, 0.85) [13, 24]: These widely used full and short risk scores were 
developed in individuals living with HIV who were not previously exposed to a potentially 
nephrotoxic antiretroviral agent and included nine and six predictor variables, respectively. In 
contrast to these two CKD risk scores, we used a set of machine learning algorithms and 
short-term prediction horizons ─ accounting for individuals with any antiretroviral treatment 
status and incorporating a variety of static and time-changing variables. These various short-
term prediction horizons may be useful to differentiate acute and chronic kidney disease and 
to evaluate the dynamics and plausibility of machine learning predictions in single 
individuals over time. For individual CKD predictions, we achieved moderate to excellent 
discrimination with the given machine learning models. Therefore, our models can be 
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18 
investigated as part of a subsequent implementation study to assess the clinical utility and 
validity of the present machine learning models ─ also for complex cases (table 3).  
 
Of interest, as illustrated in the variable importance plot of the gradient boosting model 
(figure 3), we observed a number of predictors, which are well-established risk factors for 
CKD (e.g. treatment with tenofovir disoproxil fumarate containing regimens [25]) as well as 
proxy variables and markers, which may not have a direct effect on CKD development (e.g. 
alkaline phosphatase). This observation highlights that predictive machine learning models 
may help to build novel causal hypotheses, which can be validated in subsequent causal 
studies. However, machine learning predictions and corresponding variable importance plots 
should not be used per se for causal inference, as it requires expert guidance and causal 
concepts.  
 
While developing machine learning models for CKD prediction, we faced two main 
challenges. Firstly, the preparation and structuring of the datasets for machine learning 
training was time-consuming, as real-world HIV cohort data include a multitude of static and 
dynamic data, which are often measured irregularly. Nonetheless, we believe that our data 
representation can be valuable for future machine learning investigations relying on (HIV) 
cohort databases. Secondly, the machine learning model training and selection was 
computing-intensive and required a high-performance computing cluster. 
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19 
Our study has some limitations. Firstly, our machine learning predictions models for CKD 
may not be generalisable to other healthcare settings and populations; specifically, the coding 
practices and parameters may differ between HIV cohorts, which may complicate the 
application of the same machine learning prediction models across HIV cohorts. Therefore, 
we did not intend to externally validate our machine learning prediction models as part of this 
proof-of-concept study. Secondly, as we used short prediction horizons, target leakage (i.e. 
models include information that is not yet available at the time of prediction) can result in 
biased and often too optimistic predictive performances. To safeguard against target leakage, 
we included only variables that were known at the prediction day [26]. However, we cannot 
exclude the possibility that a few parameters in our machine learning models (e.g. laboratory 
values) would be reported to the treating physician and/or clinical decision support tool some 
minutes or hours after a potential CKD prediction. Thirdly, follow-up studies should consider 
including proteinuria in the CKD outcome definition to capture CKD at earlier stages. With 
the present models, we are unable to predict proteinuria. Fourthly, a higher eGFR threshold 
>60 ml/min/1.73m2 could have been chosen for patient selection to prevent immediate 
switches from the at risk status to the CKD status; however, this would have excluded a 
substantial proportion of individuals in the SHCS, which are at highest risk of eGFR 
deterioration.  Lastly, our machine learning model training did not include genetic data (or 
other –omics data), which might have further improved the machine learning CKD 
predictions but which are often unavailable for a majority of individuals [27].  
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CONCLUSION 
In people living with HIV, we observed state-of-the-art performances in forecasting 
individual CKD onsets with different machine learning algorithms: The underlying machine 
learning methods may help to advance personalised predictions of co-morbidities in various 
populations.   
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FIGURE LEGENDS  
Figure 1: Study population   
 
Abbreviations: SHCS, Swiss HIV Cohort Study.  
a Calculated using the ‘Chronic Kidney Disease Epidemiology Collaboration’ equation.  
b We defined the baseline as the first creatinine measurement after January 1, 2002.  
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Figure 2: Overall glomerular filtration rates in people living with HIV (N = 12,761 
individuals) 
 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate [ml/min/1.73 m2].  
Note: This figure refers to the glomerular filtration rate at the last visit of the visit sequences in 
the considered observation period that is used to make predictions for 90 days, 180 days, 270 
days, and 365 days ahead subsequently. The middle line and box indicate the median and 
interquartile range, respectively. Whiskers cover the 1.5 interquartile range.  
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Figure 3: Variable importance plot of the gradient boosting model; 180 days prediction 
horizon  
 
Abbreviations: GFR, glomerular filtration rate; SHAP, shapley additive explanation; std, 
standard deviation.  
 
Note: This hypothesis-generating plot is for illustration purposes only. Suffix ‘2’ signifies that 
information from the latest visit was used, whereas suffix ‘1’ signifies that information from the 
preceding (penultimate) visit was used, both specified with respect to the visit sequence in the 
considered observation period. The different statistics (the median, standard deviation for 
numeric and max for the nominal variables) were computed for all the remaining visits in the 
target observed hospital visit sequence. The SHAP values describes for each variable and 
individual the change in the expected model prediction when conditioning on that variable.   
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Table 1: Main characteristics of the study population  
 
Variable/category  All 
(N = 12,761) 
Individuals without CKDa 
(N = 11,569) 
Individuals with CKDa 
(N = 1,192) 
N / median IQR / %  N / median IQR / % N / median IQR / % 
Age in years Baseline 
End of follow-up 
39 33 to 46 48 33 to 45 38 40 to 57 
49 41 to 56 56 41 to 55 49 50 to 65 
Sex Male 9,156 72 8,319 72 837 70 
Female 3,605 28 3,250 28 355 30 
Ethnicity White 9,964 78 8,851 77 1,113 93 
Black 1,825 14 1,783 15 42 4 
Hispanic 444 3 433 4 11 1 
Asian 482 4 458 4 24 2 
Other/unknown 46 0.4 44 0.4 2 0.2 
Intravenous drug use prior to HIV diagnosis  Yes 2,287 18 2,047 18 240 20 
No 10,408 82 9,465 82 943 79 
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Unknown  66 0.005 57 0.005 9 0.008 
Ever smoked  Yes 7,906 62 7,158 62 748 63 
No 4,815 38 4,372 38 443 37 
Unknown 40 0.3 39 0.3 1 0.1 
Hypertension Yes 729 5.7 575 5.7 154 12.9 
No 11,963 94 10,928 94 1,035 86.8 
Unknown  69 0.5 66 0.5 3 0.3 
eGFRb 
(ml/min/1.73m2) 
Baseline 
End of study 
103 90 to 114 105 92 to 115 84 73 to 96 
90 75 to 104 93 80 to 106 55 50 to 58 
CD4 count (cells/µl) Baseline 407 252 to 597 410 255 to 600 366 228 to 561 
End of study 615 426 to 830 621 437 to 839 536 362 to 759 
Viral load  
(copies/ml) 
Baseline 883 0 to 35,173 1,040 0 to 36,000 174 0 to 23,459 
End of study 0 0 to 0 0 0 to 0 0 0 to 0 
Hepatitis B Positive 510 4 464 4 46 4 
 
Negative 8,208 64 7,563 65 645 54 
 
Unknown 4,043 32 3,542 30 501 42 
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Hepatitis C Positive 1,407 11 1,272 11 135 11 
 
Negative 10,022 79 9,142 79 880 74 
 
Unknown 1,332 10 1,155 10 177 15 
Ever exposed to TDF 
Baseline 
End of study 
2,259 
9,800 
18 
77 
2,100 
8,814 
18 
76 
159 
986 
13 
83 
Ever exposed to ATV/r 
Baseline 
End of study 
481 
3,629 
4 
28 
441 
3,135 
4 
27 
40 
494 
3 
41 
Ever exposed to LPV/r 
Baseline 
End of study 
1,783 
4,043 
14 
32 
1,577 
3,604 
14 
31 
206 
439 
17 
37 
Abbreviations: ATV/r, atazanavir/ritonavir; CD4, cluster of differentiation 4; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; 
HIV, human immunodeficiency virus, IQR, interquartile range; LPV/r, lopinavir/ritonavir; TDF, tenofovir disoproxil fumarate.  
 
Note: All values are presented at baseline if not stated otherwise. We defined the baseline as the first creatinine measurement after January 1, 2002. Some 
potential risk factors are not presented, as these variables were not recorded during the entire study period.  
 
a Within the observation period.  
b Calculated using the ‘Chronic Kidney Disease Epidemiology Collaboration’ equation.   
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Table 2: Performance of models to predict chronic kidney disease across different prediction horizons (N = 1,276 individuals; test set)  
Algorithm  Visits used  Imputation 
method  
F1-
score  
Precisio
n 
Reca
ll 
ROC-
AUC 
PR-
AUC 
Prediction 90 days in advance 
Data-driven machine learning models (full 
models) 
 
─ Multilayer perceptron  Last 2 visitsa  Zero imputation 0.782 0.703 0.879 0.979 0.829 
Median forward  0.847 0.858 0.836 0.990 0.890 
─ Gradient boosting Last 2 visitsa Zero imputation 0.874 0.852 0.897 0.994 0.933 
Median forward  0.890 0.875 0.905 0.996 0.956 
─ Random forest Last 2 visitsa Zero imputation 0.583 0.942 0.422 0.995 0.943 
Median forward  0.836 0.918 0.767 0.994 0.931 
─ Elastic net  Last 2 visitsa Zero imputation 0.774 0.649 0.957 0.984 0.861 
Median forward  0.846 0.800 0.897 0.992 0.904 
─ Bidirectional recurrent neural network Full sequence; all previous 
visits  
Zero imputation 0.818 0.786 0.853 0.984 0.874 
Median forward  0.856 0.819 0.897 0.989 0.916 
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─ Bidirectional attention recurrent neural 
network 
Full sequence; all previous 
visits  
Zero imputation 
Median forward  
0.803 
0.852 
0.797 
0.812 
0.810 
0.897 
0.981 
0.986 
0.867 
0.901 
Manually built logistic regression model (short 
model)  
Last 2 visitsa None 0.807 0.689 0.974 0.990 0.881 
      
Prediction 180 days in advance 
Data-driven machine learning models (full 
models) 
 
─ Multilayer perceptron Last 2 visitsa Zero imputation 0.719 0.716 0.722 0.960 0.777 
Median forward  0.718 0.798 0.652 0.963 0.803 
─ Gradient boosting Last 2 visitsa Zero imputation 0.656 0.859 0.530 0.969 0.833 
Median forward  0.789 0.815 0.765 0.970 0.860 
─ Random forest Last 2 visitsa Zero imputation 0.115 >0.999 0.061 0.955 0.803 
Median forward  0.677 0.844 0.565 0.968 0.814 
─ Elastic net  Last 2 visitsa Zero imputation 0.698 0.629 0.783 0.952 0.768 
Median forward  0.767 0.777 0.757 0.959 0.787 
─ Bidirectional recurrent neural network Full sequence; all previous Zero imputation 0.722 0.732 0.713 0.965 0.759 
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visits  Median forward  0.718 0.706 0.730 0.956 0.730 
─ Bidirectional attention recurrent neural 
network 
Full sequence; all previous 
visits  
Zero imputation 
Median forward  
0.694 
0.721 
0.720 
0.712 
0.670 
0.730 
0.963 
0.945 
0.755 
0.792 
Manually built logistic regression model (short 
model)  
Last 2 visitsa None  
 
0.559 
 
0.405 
 
0.904 
 
0.934 
 
0.646 
 
Prediction 270 days in advance 
Data-driven machine learning models (full 
models) 
 
─ Multilayer perceptron Last 2 visitsa Zero imputation 0.678 0.634 0.728 0.948 0.666 
Median forward  0.660 0.753 0.588 0.952 0.735 
─ Gradient boosting Last 2 visitsa Zero imputation 0.290 0.833 0.175 0.944 0.702 
Median forward  0.689 0.745 0.640 0.957 0.728 
─ Random forest Last 2 visitsa Zero imputation 0.068 >0.999 0.035 0.928 0.661 
Median forward  0.578 0.788 0.456 0.955 0.739 
─ Elastic net  Last 2 visitsa Zero imputation 0.647 0.566 0.754 0.942 0.702 
Median forward 0.650 0.756 0.570 0.943 0.716 
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─ Bidirectional recurrent neural network Full sequence; all previous 
visits  
Zero imputation 0.605 0.581 0.632 0.938 0.649 
Median forward 0.661 0.632 0.693 0.940 0.737 
─ Bidirectional attention recurrent neural 
network 
Full sequence; all previous 
visits  
Zero imputation 0.664 0.630 0.702 0.931 0.678 
Median forward  0.664 0.699 0.632 0.934 0.693 
Manually built logistic regression model (short 
model)  
Last 2 visitsa None  
 
0.453 
 
0.310 
 
0.842 
 
0.893 
 
0.504 
 
Prediction 365 days in advance 
Data-driven machine learning models (full 
models) 
 
─ Multilayer perceptron Last 2 visitsa Zero imputation 0.641 0.691 0.598 0.950 0.699 
Median forward 0.628 0.776 0.527 0.950 0.722 
─ Gradient boosting Last 2 visitsa Zero imputation 0.220 0.933 0.125 0.945 0.700 
Median forward 0.619 0.663 0.580 0.941 0.710 
─ Random forest Last 2 visitsa Zero imputation 0.018 >0.999 0.009 0.941 0.705 
Median forward  0.527 0.800 0.393 0.952 0.725 
─ Elastic net  Last 2 visitsa Zero imputation 0.588 0.626 0.554 0.938 0.673 
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Median forward 0.512 0.808 0.375 0.935 0.681 
─ Bidirectional recurrent neural network  Full sequence; all previous 
visits  
Zero imputation 0.606 0.656 0.562 0.945 0.631 
Median forward  0.678 0.661 0.696 0.935 0.694 
─ Bidirectional attention recurrent neural 
network 
Full sequence; all previous 
visits  
Zero imputation 0.600 0.643 0.562 0.928 0.632 
Median forward  0.633 0.554 0.738 0.926 0.692 
Manually built logistic regression model (short 
model)  
Last 2 visitsa None  
 
0.423 
 
0.286 
 
0.812 
 
0.883 
 
0.468 
 
Abbreviations: ROC-AUC, area under the receiver operating characteristic curve; PR-AUC; area under the precision-recall curve.  
 
a And summary statistics from earlier visits during the target observation period, as detailed in the methods section.   
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Table 3: How would you decide? Predicted and observed chronic kidney disease outcomes among three complex cases across prediction horizons 
(gradient boosting model estimates for illustration purposes)  
Individual Predicted outcome (CKD probability) Observed outcome  Brief interpretation and key 
predictor for single individuals Prediction horizon Prediction horizon 
90 days 180 days 270 days 365 days 90 days 180 days 270 days 365 days 
1 No CKD  
(0.34) 
CKD  
(0.99) 
CKD  
(0.51) 
No CKD  
(0.01) 
CKD  
 
CKD  
 
CKD  
 
CKD  
 
Platelet counts and various 
hematological parameters were 
strong predictors for CKD in this 
individual; however, this did not 
prevent false negative predictions at 
90 and 365 days. There were dozens 
of moderate predictors of unclear 
clinical relevance: These factors have 
cancelled out at 365 days, as some 
were preventive and others suggested 
an incremental CKD risk. This 
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example highlights that a clinician 
should review every machine 
learning prediction.   
2 No CKD  
(0.18) 
No CKD  
(0.00) 
No CKD  
(0.00) 
No CKD  
(0.00) 
No CKD  
 
No CKD  
 
No CKD  
 
No CKD  
 
Absent cardiovascular risk factors 
(e.g. smoking) were strong predictors 
against CKD development. However, 
there were dozens of moderate 
predictors (potential preventive 
factors and risk factors) of unclear 
clinical relevance. The low CKD 
probability score across prediction 
horizons, together with a careful 
review of medical records, may be an 
indication for clinicians that CKD 
development is unlikely.  
3 No CKD  CKD  No CKD  No CKD  No CKD  No CKD  No CKD  No CKD  Cardiovascular risk factors (e.g. high 
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(0.28) (0.71) (0.00) (0.02)     systolic blood pressure) and alcohol 
binge drinking increased the 
predicted CKD probability 
substantially ─ resulting in a false 
positive prediction at 180 days; 
however, high preceding eGFR 
values were strong predictors against 
CKD across prediction horizons.  
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.   
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Figure 1 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiaa236/5835004 by E-Library Insel user on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
41 
Figure 2 
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Figure 3 
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